Breaking News

Sunday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 05:55
07/12/20
07/12
05:55
07/12/20
05:55
ABEO

Abeona Therapeutics

$3.01 /

-0.34 (-10.15%)

, AMGN

Amgen

$249.23 /

-2.03 (-0.81%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$87.02 /

-0.3 (-0.34%)

, PFE

Pfizer

$33.84 /

+0.39 (+1.17%)

, SNY

Sanofi

$50.32 /

-0.24 (-0.47%)

, VRCA

Verrica Pharmaceuticals

$9.51 /

+0.75 (+8.56%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$249.23 /

-2.03 (-0.81%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.84 /

+0.39 (+1.17%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

  • 20
    Dec
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

Saturday
Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 04:55
07/11/20
07/11
04:55
07/11/20
04:55
ABEO

Abeona Therapeutics

$3.01 /

-0.34 (-10.15%)

, AMGN

Amgen

$249.23 /

-2.03 (-0.81%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$87.02 /

-0.3 (-0.34%)

, PFE

Pfizer

$33.84 /

+0.39 (+1.17%)

, SNY

Sanofi

$50.32 /

-0.24 (-0.47%)

, VRCA

Verrica Pharmaceuticals

$9.51 /

+0.75 (+8.56%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$249.23 /

-2.03 (-0.81%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.84 /

+0.39 (+1.17%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

ABEO Abeona Therapeutics
$3.01 /

-0.34 (-10.15%)

  • 20
    Dec
SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

VRCA Verrica Pharmaceuticals
$9.51 /

+0.75 (+8.56%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

SNY Sanofi
$50.32 /

-0.24 (-0.47%)

PFE Pfizer
$33.84 /

+0.39 (+1.17%)

NVS Novartis
$87.02 /

-0.3 (-0.34%)

AMGN Amgen
$249.23 /

-2.03 (-0.81%)

Friday
Conference/Events
Society for Pediatric Dermatology to hold virtual meeting » 10:18
07/10/20
07/10
10:18
07/10/20
10:18
ABEO

Abeona Therapeutics

$3.02 /

-0.33 (-9.85%)

, AMGN

Amgen

$247.24 /

-4.025 (-1.60%)

, DRMT

Dermavant

$0.00 /

+ (+0.00%)

, NVS

Novartis

$86.61 /

-0.71 (-0.81%)

, PFE

Pfizer

$33.69 /

+0.24 (+0.72%)

, SNY

Sanofi

$50.25 /

-0.31 (-0.61%)

, VRCA

Verrica Pharmaceuticals

$9.70 /

+0.94 (+10.73%)

45th Annual Virtual…

45th Annual Virtual Meeting: SPD2020 will be held on July 10-12. Webcast Link

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

DRMT Dermavant
$0.00 /

+ (+0.00%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
AMGN Amgen
$247.24 /

-4.025 (-1.60%)

07/02/20 Citi
Citi sees 'considerable amount of investor interest' coming back to Amgen
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Mizuho
Amgen patent win worth $5-$12 per share, says Mizuho
07/01/20 Goldman Sachs
Court ruling removes overhang for Amgen, says Goldman Sachs
DRMT Dermavant
$0.00 /

+ (+0.00%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
PFE Pfizer
$33.69 /

+0.24 (+0.72%)

07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
07/08/20 Argus
Pfizer positioned for stronger revenue growth in 2021 and beyond, says Argus
07/07/20 Needham
Vaxcyte initiated with a Buy at Needham
07/02/20 B. Riley FBR
Novavax should be bought on weakness from Pfizer data, says B. Riley FBR
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/26/20 SunTrust
Translate Bio initiated with a Buy at SunTrust
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

06/30/20 H.C. Wainwright
Verrica Pharmaceuticals price target lowered to $18 from $24 at H.C. Wainwright
06/24/20 Northland
Verrica Pharmaceuticals initiated with an Outperform at Northland
03/24/20
Fly Intel: Top five analyst initiations
03/24/20 Needham
Verrica Pharmaceuticals initiated with a Buy at Needham
VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

ABEO Abeona Therapeutics
$3.02 /

-0.33 (-9.85%)

  • 20
    Dec
SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

VRCA Verrica Pharmaceuticals
$9.70 /

+0.94 (+10.73%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

SNY Sanofi
$50.25 /

-0.31 (-0.61%)

PFE Pfizer
$33.69 /

+0.24 (+0.72%)

NVS Novartis
$86.61 /

-0.71 (-0.81%)

AMGN Amgen
$247.24 /

-4.025 (-1.60%)

Hot Stocks
Abeona Therapeutics announces two presentations related to RDEB program » 07:34
07/10/20
07/10
07:34
07/10/20
07:34
ABEO

Abeona Therapeutics

$3.35 /

-0.07 (-2.05%)

Abeona Therapeutics…

Abeona Therapeutics announced that two poster presentations related to its clinical program for recessive dystrophic epidermolysis bullosa, or RDEB, were featured at the Society for Pediatric Dermatology, or SPD, 45th annual meeting. The first poster includes a detailed analysis of patients with RDEB in the EB-101 Phase 1/2a trial showing that wound healing following EB-101 treatment was associated with improved long-term pain relief. A separate poster provides insights on the significant disease burden associated with RDEB, highlighting data from a literature review on the clinical characteristics, humanistic consequences and economic impact of living with RDEB on patients and their families. The company alsopresented findings from a literature review of 65 studies that provide new insights on the disease burden from the perspective of patients with RDEB and their families. Key observations of the clinical, humanistic and economic burden of RDEB include: Large, chronic wounds comprise a major clinical burden of RDEB and are correlated with pain.Many patients experience anxiety and depression. Parents of children with RDEB reported negative effects on their relationship, choosing to not have more children. 50% of U.S. families characterized the economic impact of managing RDEB as "high" or "severe."

ShowHide Related Items >><<
ABEO Abeona Therapeutics
$3.35 /

-0.07 (-2.05%)

ABEO Abeona Therapeutics
$3.35 /

-0.07 (-2.05%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
ABEO Abeona Therapeutics
$3.35 /

-0.07 (-2.05%)

  • 20
    Dec
Over a week ago
Hot Stocks
Abeona Therapeutics appoints Michael Amoroso as CCO » 07:36
07/09/20
07/09
07:36
07/09/20
07:36
ABEO

Abeona Therapeutics

$3.42 /

+0.025 (+0.74%)

, GILD

Gilead

$75.63 /

-0.84 (-1.10%)

Abeona Therapeutics…

Abeona Therapeutics (ABEO) announced the appointment of Michael Amoroso as senior VP and chief commercial officer, or CCO, effective immediately. Amoroso brings to Abeona over 20 years of product commercialization experience in the biotechnology and pharmaceutical industries, most recently as senior VP and head of worldwide commercial, cell therapy at Kite, a Gilead company (GILD). Amoroso will have overall responsibility for building the company's commercial organization, developing the commercialization strategy for EB-101, its autologous, gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa and its lead product candidate, as well as leading pre-commercial planning for its investigational adeno-associated virus vector-based gene therapies.

ShowHide Related Items >><<
GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABEO Abeona Therapeutics
$3.42 /

+0.025 (+0.74%)

ABEO Abeona Therapeutics
$3.42 /

+0.025 (+0.74%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
GILD Gilead
$75.63 /

-0.84 (-1.10%)

06/30/20 SVB Leerink
Gilead's remdesivir price gives confidence in revenue, says SVB Leerink
06/30/20 Wells Fargo
Remdesivir pricing 'a responsible public health decision,' says Wells Fargo
06/29/20 Piper Sandler
Piper says Gilead sale to HHS should make remdesivir opportunity 'more tangible'
06/29/20 RBC Capital
RBC says HIV, other franchises more critical drivers of Gilead than remdesivir
GILD Gilead
$75.63 /

-0.84 (-1.10%)

ABEO Abeona Therapeutics
$3.42 /

+0.025 (+0.74%)

  • 20
    Dec
GILD Gilead
$75.63 /

-0.84 (-1.10%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

GILD Gilead
$75.63 /

-0.84 (-1.10%)

Hot Stocks
Abeona Therapeutics restarts patient enrollment in VIITAL study of EB-101 » 07:35
07/08/20
07/08
07:35
07/08/20
07:35
ABEO

Abeona Therapeutics

$3.40 /

+0.285 (+9.16%)

Abeona Therapeutics…

Abeona Therapeutics announced recent updates on its clinical programs, highlighted by the restart of patient enrollment in the company's pivotal Phase 3 VIITAL study of EB-101, its autologous, gene-corrected cell therapy, for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB. Enrollment in the VIITAL study at Stanford University Medical Center was paused in March in order to redirect healthcare resources to COVID-19 patients and to ensure the safety of study participants and site staff. Abeona also announced that two ongoing MPS III Phase 1/2 clinical trials of its investigational adeno-associated virus, or AAV-based gene therapies, ABO-102 and ABO-101, have continued to treat patients, with additional enrollment expected in the programs in the coming weeks. In June, the tenth patient was dosed in cohort 3 of the ABO-102 Transpher A study for MPS IIIA, bringing the total to 16 patients. The company previously reported in May that additional patients were treated in dose cohort 3 of the Transpher A study and the ABO-101 Transpher B study for MPS IIIB, bringing the total enrollment in the Transpher B study to nine children to date.

ShowHide Related Items >><<
ABEO Abeona Therapeutics
$3.40 /

+0.285 (+9.16%)

ABEO Abeona Therapeutics
$3.40 /

+0.285 (+9.16%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
ABEO Abeona Therapeutics
$3.40 /

+0.285 (+9.16%)

  • 20
    Dec
Hot Stocks
Abeona Therapeutics appoints George Migausky, Paul Mann to board of directors » 07:37
06/17/20
06/17
07:37
06/17/20
07:37
ABEO

Abeona Therapeutics

$3.13 /

+0.01 (+0.32%)

, PTE

PolarityTE

$1.44 /

+0.015 (+1.06%)

, OCUL

Ocular Therapeutix

$8.83 /

+0.57 (+6.90%)

Abeona Therapeutics…

Abeona Therapeutics (ABEO) announced Board of Director appointments that strengthen and expand the Company's leadership. George Migausky and Paul Mann were appointed as independent directors, effective June 17, 2020. In addition to their Board service, Mr. Migausky will serve as Chairman of the Company's Audit Committee and Mr. Mann will serve as a member of the Audit Committee. Most recently, Migausky served as interim CFO of Ocular Therapeutix (OCUL) and Mann served as CFO at PolarityTE (PTE).

ShowHide Related Items >><<
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

06/05/20 Cantor Fitzgerald
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald
05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

05/04/20 H.C. Wainwright
PolarityTE downgraded to Neutral from Buy at H.C. Wainwright
05/01/20 Oppenheimer
PolarityTE downgraded to Perform on limited visibility at Oppenheimer
05/01/20 Oppenheimer
PolarityTE downgraded to Perform from Outperform at Oppenheimer
04/20/20 Oppenheimer
Avita Medical initiated with an Outperform at Oppenheimer
OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

05/15/20 Piper Sandler
Ocular Therapeutix early OTX-TKI data encouraging, says Piper Sandler
05/08/20 Piper Sandler
Ocular Therapeutix long-term opportunity intact, says Piper Sandler
04/29/20 H.C. Wainwright
Ocular Therapeutix price target raised to $10 from $8 at H.C. Wainwright
04/28/20 Piper Sandler
Ocular Therapeutix data warrant discussions with FDA, says Piper Sandler
PTE PolarityTE
$1.44 /

+0.015 (+1.06%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

ABEO Abeona Therapeutics
$3.13 /

+0.01 (+0.32%)

OCUL Ocular Therapeutix
$8.83 /

+0.57 (+6.90%)

Over a month ago
Recommendations
Abeona could trade higher on Lysogene clinical hold, says Cantor Fitzgerald » 08:14
06/05/20
06/05
08:14
06/05/20
08:14
ABEO

Abeona Therapeutics

$2.91 /

-0.025 (-0.85%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Kristen Kluska thinks shares of Abeona Therapeutics will trade higher on Friday after the announcement from rival Lysogene that the Phase 2/3 trial of LYS-SAF302 is on clinical hold. While Kluska remains bullish on gene therapy and thinks Abeona could form a partnership with earlier-stage programs, she remains on the sidelines with a Neutral rating as she has concerns about the lead programs and the company's financial status.

ShowHide Related Items >><<
ABEO Abeona Therapeutics
$2.91 /

-0.025 (-0.85%)

ABEO Abeona Therapeutics
$2.91 /

-0.025 (-0.85%)

05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
ABEO Abeona Therapeutics
$2.91 /

-0.025 (-0.85%)

Conference/Events
American Society of Gene & Cell Therapy to hold virtual meeting » 05:55
05/15/20
05/15
05:55
05/15/20
05:55
A

Agilent

$81.59 /

+1.44 (+1.80%)

, ABEO

Abeona Therapeutics

$3.21 /

-0.065 (-1.98%)

, ADVM

Adverum Biotechnologies

$17.20 /

-0.18 (-1.04%)

, AGEEF

Halo Labs

$0.00 /

+ (+0.00%)

, AVRO

Avrobio

$15.58 /

-1.19 (-7.10%)

, BIO

Bio-Rad

$455.80 /

+2.52 (+0.56%)

, BMRN

BioMarin

$91.67 /

-3.01 (-3.18%)

, CRL

Charles River

$163.30 /

+3.07 (+1.92%)

, CTLT

Catalent

$70.04 /

-1.08 (-1.52%)

, MGTA

Magenta Therapeutics

$8.67 /

-0.305 (-3.40%)

, PI

Impinj

$22.94 /

+1.01 (+4.61%)

, QURE

uniQure

$56.16 /

-0.56 (-0.99%)

, SRPT

Sarepta

$127.15 /

-1.08 (-0.84%)

, TECH

Bio-Techne

$261.68 /

-0.7 (-0.27%)

, TMO

Thermo Fisher

$336.49 /

+2.31 (+0.69%)

, RARE

Ultragenyx

$64.57 /

+0.44 (+0.69%)

23rd Annual Virtual…

23rd Annual Virtual Meeting of ASGCT 2020 will be held May 12-15. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

TECH Bio-Techne
$261.68 /

-0.7 (-0.27%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

RARE Ultragenyx
$64.57 /

+0.44 (+0.69%)

QURE uniQure
$56.16 /

-0.56 (-0.99%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

MGTA Magenta Therapeutics
$8.67 /

-0.305 (-3.40%)

CTLT Catalent
$70.04 /

-1.08 (-1.52%)

CRL Charles River
$163.30 /

+3.07 (+1.92%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

BIO Bio-Rad
$455.80 /

+2.52 (+0.56%)

AVRO Avrobio
$15.58 /

-1.19 (-7.10%)

ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

ABEO Abeona Therapeutics
$3.21 /

-0.065 (-1.98%)

A Agilent
$81.59 /

+1.44 (+1.80%)

A Agilent
$81.59 /

+1.44 (+1.80%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
ABEO Abeona Therapeutics
$3.21 /

-0.065 (-1.98%)

05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
04/28/20 Goldman Sachs
Adverum Biotechnologies initiated with a Buy at Goldman Sachs
AGEEF Halo Labs
$0.00 /

+ (+0.00%)

AVRO Avrobio
$15.58 /

-1.19 (-7.10%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BIO Bio-Rad
$455.80 /

+2.52 (+0.56%)

04/08/20 Jefferies
Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies
03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
CRL Charles River
$163.30 /

+3.07 (+1.92%)

05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
04/21/20 Jefferies
Jefferies downgrades Charles River to Hold after 51% rally from lows
CTLT Catalent
$70.04 /

-1.08 (-1.52%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MGTA Magenta Therapeutics
$8.67 /

-0.305 (-3.40%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
PI Impinj
$22.94 /

+1.01 (+4.61%)

04/28/20 Needham
Impinj price target raised to $25 from $19 at Needham
04/28/20 Canaccord
Impinj price target lowered to $35 from $40 at Canaccord
04/27/20 Piper Sandler
Impinj price target lowered to $29 from $44 at Piper Sandler
03/10/20 Morgan Stanley
Morgan Stanley lowers semiconductor estimates to reflect COVID-19 disruption
QURE uniQure
$56.16 /

-0.56 (-0.99%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

05/07/20 Nomura Instinet
Nomura sees double in Sarepta shares, says buy on earnings selloff
04/28/20 JMP Securities
JMP cautious on feasibility of Sarepta PPMO constructs being used in COVID fight
04/27/20 Citi
Sarepta upcoming PPMO readout unlikely to be catalyst, says Citi
03/30/20 Mizuho
Sarepta initiated with a Buy at Mizuho
TECH Bio-Techne
$261.68 /

-0.7 (-0.27%)

05/14/20 Benchmark
Benchmark sees 'multiple ways to play COVID-19' for Bio-Techne, starts at Buy
05/14/20 Benchmark
Bio-Techne initiated with a Buy at Benchmark
04/20/20 Craig-Hallum
Bio-Techne price target lowered to $211 from $218 at Craig-Hallum
03/30/20 Wells Fargo
Bio-Techne price target lowered to $190 from $225 at Wells Fargo
TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
RARE Ultragenyx
$64.57 /

+0.44 (+0.69%)

05/13/20 Piper Sandler
Ultragenyx DTX-301 update 'incrementally positive,' says Piper Sandler
01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

TECH Bio-Techne
$261.68 /

-0.7 (-0.27%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

RARE Ultragenyx
$64.57 /

+0.44 (+0.69%)

QURE uniQure
$56.16 /

-0.56 (-0.99%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

MGTA Magenta Therapeutics
$8.67 /

-0.305 (-3.40%)

CTLT Catalent
$70.04 /

-1.08 (-1.52%)

CRL Charles River
$163.30 /

+3.07 (+1.92%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

BIO Bio-Rad
$455.80 /

+2.52 (+0.56%)

AVRO Avrobio
$15.58 /

-1.19 (-7.10%)

ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

ABEO Abeona Therapeutics
$3.21 /

-0.065 (-1.98%)

A Agilent
$81.59 /

+1.44 (+1.80%)

TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

CTLT Catalent
$70.04 /

-1.08 (-1.52%)

A Agilent
$81.59 /

+1.44 (+1.80%)

TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

ADVM Adverum Biotechnologies
$17.20 /

-0.18 (-1.04%)

A Agilent
$81.59 /

+1.44 (+1.80%)

TMO Thermo Fisher
$336.49 /

+2.31 (+0.69%)

SRPT Sarepta
$127.15 /

-1.08 (-0.84%)

QURE uniQure
$56.16 /

-0.56 (-0.99%)

PI Impinj
$22.94 /

+1.01 (+4.61%)

BMRN BioMarin
$91.67 /

-3.01 (-3.18%)

A Agilent
$81.59 /

+1.44 (+1.80%)

Conference/Events
American Society of Gene & Cell Therapy to hold virtual meeting » 04:55
05/14/20
05/14
04:55
05/14/20
04:55
A

Agilent

$80.15 /

+0.32 (+0.40%)

, ABEO

Abeona Therapeutics

$3.28 /

+0.235 (+7.73%)

, ADVM

Adverum Biotechnologies

$17.38 /

-1.4 (-7.45%)

, AGEEF

Halo Labs

$0.00 /

+ (+0.00%)

, AVRO

Avrobio

$16.77 /

-0.22 (-1.29%)

, BIO

Bio-Rad

$453.28 /

-8.19 (-1.77%)

, BMRN

BioMarin

$94.68 /

-1.49 (-1.55%)

, CRL

Charles River

$160.23 /

-1.16 (-0.72%)

, CTLT

Catalent

$71.12 /

+ (+0.00%)

, MGTA

Magenta Therapeutics

$8.98 /

-0.4 (-4.27%)

, PI

Impinj

$21.93 /

-1.94 (-8.13%)

, QURE

uniQure

$56.72 /

-4.33 (-7.09%)

, SRPT

Sarepta

$128.23 /

-4.5 (-3.39%)

, TECH

Bio-Techne

$262.38 /

-10.54 (-3.86%)

, TMO

Thermo Fisher

$334.18 /

+2.23 (+0.67%)

, RARE

Ultragenyx

$64.13 /

-2.07 (-3.13%)

23rd Annual Virtual…

23rd Annual Virtual Meeting of ASGCT 2020 will be held May 12-15. Webcast Link

ShowHide Related Items >><<
TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

TECH Bio-Techne
$262.38 /

-10.54 (-3.86%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

RARE Ultragenyx
$64.13 /

-2.07 (-3.13%)

QURE uniQure
$56.72 /

-4.33 (-7.09%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

MGTA Magenta Therapeutics
$8.98 /

-0.4 (-4.27%)

CTLT Catalent
$71.12 /

+ (+0.00%)

CRL Charles River
$160.23 /

-1.16 (-0.72%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

BIO Bio-Rad
$453.28 /

-8.19 (-1.77%)

AVRO Avrobio
$16.77 /

-0.22 (-1.29%)

ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

ABEO Abeona Therapeutics
$3.28 /

+0.235 (+7.73%)

A Agilent
$80.15 /

+0.32 (+0.40%)

A Agilent
$80.15 /

+0.32 (+0.40%)

03/30/20 Wells Fargo
Agilent price target lowered to $82 from $100 at Wells Fargo
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/24/20 Needham
Agilent downgraded to Hold from Buy at Needham
02/19/20 Piper Sandler
Agilent price target raised to $96 from $86 at Piper Sandler
ABEO Abeona Therapeutics
$3.28 /

+0.235 (+7.73%)

05/08/20 Jefferies
Abeona 'one of most underappreciated' in late-stage gene therapy, says Jefferies
12/30/19 H.C. Wainwright
Abeona Therapeutics price target lowered to $11 from $15 at H.C. Wainwright
12/20/19 Cantor Fitzgerald
Abeona financing to lessen takeover chartter, says Cantor Fitzgerald
12/10/19 Cantor Fitzgerald
Abeona Therapeutics assumed with a Neutral at Cantor Fitzgerald
ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

05/12/20 RBC Capital
Adverum Biotechnologies initiated with an Outperform at RBC Capital
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
05/05/20 SunTrust
Adverum Biotechnologies upgraded to Buy from Hold at SunTrust
04/28/20 Goldman Sachs
Adverum Biotechnologies initiated with a Buy at Goldman Sachs
AGEEF Halo Labs
$0.00 /

+ (+0.00%)

AVRO Avrobio
$16.77 /

-0.22 (-1.29%)

03/31/20 H.C. Wainwright
Avrobio downgraded to Neutral from Buy at H.C. Wainwright
03/17/20 Janney Montgomery Scott
Avrobio weakness a buying opportunity, says Janney Montgomery Scott
02/19/20 Nomura Instinet
Avrobio price target raised to $50 from $35 at Nomura Instinet
02/11/20 Mizuho
Avrobio price target raised to $35 from $28 at Mizuho
BIO Bio-Rad
$453.28 /

-8.19 (-1.77%)

04/08/20 Jefferies
Bio-Rad COVID-19 antibody test 'could be big,' says Jefferies
03/03/20 Citi
Bio-Rad margin expansion story in early innings, says Citi
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Bio-Rad initiated with an Overweight at Wells Fargo
BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

05/08/20 Canaccord
BioMarin price target raised to $119 from $108 at Canaccord
05/01/20 Jefferies
Jefferies says valrox, vosoritide uptake may be faster than other BioMarin drugs
04/29/20 Piper Sandler
BioMarin guidance cut 'transient', says Piper Sandler
04/06/20
BioMarin participates in a conference call with Stifel
CRL Charles River
$160.23 /

-1.16 (-0.72%)

05/13/20 UBS
Charles River upgraded to Buy from Neutral at UBS
05/08/20 Baird
Charles River price target raised to $175 from $156 at Baird
05/08/20 SunTrust
Charles River price target raised to $194 from $130 at SunTrust
04/21/20 Jefferies
Jefferies downgrades Charles River to Hold after 51% rally from lows
CTLT Catalent
$71.12 /

+ (+0.00%)

05/06/20 Baird
Catalent price target raised to $74 from $63 at Baird
04/29/20 Stephens
Catalent deal with J&J could represent $600M revenue opportunity, says Stephens
04/20/20 RBC Capital
Catalent initiated with an Outperform at RBC Capital
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
MGTA Magenta Therapeutics
$8.98 /

-0.4 (-4.27%)

01/15/20 BTIG
BTIG sees 'no real reason' for Magenta Therapeutics sell-off
12/06/19 BTIG
Magenta Therapeutics initiated with a Buy at BTIG
12/06/19 Goldman Sachs
Magenta Therapeutics assumed with a Neutral at Goldman Sachs
PI Impinj
$21.93 /

-1.94 (-8.13%)

04/28/20 Needham
Impinj price target raised to $25 from $19 at Needham
04/28/20 Canaccord
Impinj price target lowered to $35 from $40 at Canaccord
04/27/20 Piper Sandler
Impinj price target lowered to $29 from $44 at Piper Sandler
03/10/20 Morgan Stanley
Morgan Stanley lowers semiconductor estimates to reflect COVID-19 disruption
QURE uniQure
$56.72 /

-4.33 (-7.09%)

03/26/20 Piper Sandler
uniQure trial delay 'comes as no surprise,' says Piper Sandler
01/23/20 Cantor Fitzgerald
Cantor sees further upside in uniQure, calls 'highly attractive' buyout candiate
12/10/19 Mizuho
uniQure price target raised to $90 from $67 at Mizuho
12/09/19 Piper Sandler
Piper says uniQure solidified 'front runner' position in Hemophilia B at ASH
SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

05/07/20 Nomura Instinet
Nomura sees double in Sarepta shares, says buy on earnings selloff
04/28/20 JMP Securities
JMP cautious on feasibility of Sarepta PPMO constructs being used in COVID fight
04/27/20 Citi
Sarepta upcoming PPMO readout unlikely to be catalyst, says Citi
03/30/20 Mizuho
Sarepta initiated with a Buy at Mizuho
TECH Bio-Techne
$262.38 /

-10.54 (-3.86%)

04/20/20 Craig-Hallum
Bio-Techne price target lowered to $211 from $218 at Craig-Hallum
03/30/20 Wells Fargo
Bio-Techne price target lowered to $190 from $225 at Wells Fargo
02/24/20 Eight Capital
Bio-Techne downgraded to Neutral from Buy at Eight Capital
01/08/20 Stephens
Bio-Techne resumed with an Overweight at Stephens
TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

04/23/20 SVB Leerink
Thermo Fisher price target raised to $365 from $330 at SVB Leerink
04/23/20 Needham
Thermo Fisher price target raised to $383 from $341 at Needham
04/21/20 Wells Fargo
Danaher price target raised to $170 from $155 at Wells Fargo
03/30/20 Wells Fargo
Thermo Fisher price target lowered to $300 from $345 at Wells Fargo
RARE Ultragenyx
$64.13 /

-2.07 (-3.13%)

05/13/20 Piper Sandler
Ultragenyx DTX-301 update 'incrementally positive,' says Piper Sandler
01/10/20 SunTrust
Ultragenyx price target raised to $80 from $75 at SunTrust
01/10/20 Piper Sandler
Ultragenyx gene therapy update 'surprisingly positive,' says Piper Sandler
12/18/19 Piper Sandler
Piper remains buyer of Ultragenyx after Royalty Pharma deal
TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

TECH Bio-Techne
$262.38 /

-10.54 (-3.86%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

RARE Ultragenyx
$64.13 /

-2.07 (-3.13%)

QURE uniQure
$56.72 /

-4.33 (-7.09%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

MGTA Magenta Therapeutics
$8.98 /

-0.4 (-4.27%)

CTLT Catalent
$71.12 /

+ (+0.00%)

CRL Charles River
$160.23 /

-1.16 (-0.72%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

BIO Bio-Rad
$453.28 /

-8.19 (-1.77%)

AVRO Avrobio
$16.77 /

-0.22 (-1.29%)

ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

ABEO Abeona Therapeutics
$3.28 /

+0.235 (+7.73%)

A Agilent
$80.15 /

+0.32 (+0.40%)

TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

CTLT Catalent
$71.12 /

+ (+0.00%)

A Agilent
$80.15 /

+0.32 (+0.40%)

TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

ADVM Adverum Biotechnologies
$17.38 /

-1.4 (-7.45%)

A Agilent
$80.15 /

+0.32 (+0.40%)

TMO Thermo Fisher
$334.18 /

+2.23 (+0.67%)

SRPT Sarepta
$128.23 /

-4.5 (-3.39%)

QURE uniQure
$56.72 /

-4.33 (-7.09%)

PI Impinj
$21.93 /

-1.94 (-8.13%)

BMRN BioMarin
$94.68 /

-1.49 (-1.55%)

A Agilent
$80.15 /

+0.32 (+0.40%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.